Idinvest Partners

Troops is a developer of digital HR software aimed at streamlining human resource management processes. The platform facilitates various HR tasks, including recruitment management, payroll processing, and the creation and electronic signing of employment contracts. By optimizing these functions, Troops enhances the relationship between organizations and their employees or candidates, thereby reducing the administrative burden on HR teams. Additionally, the software supports the planning of e-learning training content and assists in the digital onboarding of new hires, making it a comprehensive solution for modern HR needs.

Geolid is a web advertising platform aimed at supporting local businesses in France by enhancing their communication practices. The company provides tools for geolocalized advertising and search optimization, allowing major brands to digitize their networks and maintain a consistent online presence. This approach enables franchisees and small businesses to efficiently engage with their customers through a unified platform, ultimately boosting local business visibility and effectiveness. Geolid focuses on transforming how businesses communicate with consumers, ensuring that they can effectively reach their target audience in a competitive digital landscape.

SantéVet is a leader in the animal health insurance sector, established in 2003. The company specializes in providing a range of insurance policies for pets, including dogs, cats, and smaller animals like hamsters and parrots. Its offerings allow pet owners to receive total or partial reimbursement for veterinary expenses, covering incidents such as accidents, illnesses, vaccinations, and therapeutic food. With a turnover of €20 million and a workforce of over 80 employees, SantéVet is recognized for the quality of its products and services by both clients and veterinary professionals. The company holds ISO 9001 certification, reflecting its commitment to high standards in customer service and operational excellence.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon (France), that develops, manufactures and markets innovative patient monitoring systems. The core focus of APD is to provide relevant indicators pertaining to tissue perfusion to clinicians. The recent market introduction of IKORUS® monitoring system addresses a unmet need up to now, and opens new fields of investigation for physicians, enabling early detection of microcirculatory alterations and potential improvement of current therapeutic practices.

BliNK Biomedical SAS is a biotechnology company based in Lyon, France, founded in 2014. The company specializes in the discovery and development of monoclonal antibodies aimed at treating life-threatening diseases, particularly in the field of immuno-oncology. Its lead program focuses on a monoclonal antibody that targets an immune checkpoint, enhancing the body's immune response against tumors. BliNK Biomedical employs a unique B cell technology platform that facilitates the selection and isolation of specific antibody-producing cells from various species, including humans and animals. This innovative approach allows researchers to efficiently identify and develop next-generation anti-tumor therapeutics targeting novel immuno-oncology and immune-checkpoint pathways.

Okko Hotels SAS owns and operates hotels for business and leisure travelers. The company was incorporated in 2009 and is based in Paris, France with hotels in Lyon Lafayette, Nantes Chateau, Cannes Center, Grenoble Jardin HoChe, and Paris Rueil.

Advanced Perfusion Diagnostics is a medical technology company based in Lyon (France), that develops, manufactures and markets innovative patient monitoring systems. The core focus of APD is to provide relevant indicators pertaining to tissue perfusion to clinicians. The recent market introduction of IKORUS® monitoring system addresses a unmet need up to now, and opens new fields of investigation for physicians, enabling early detection of microcirculatory alterations and potential improvement of current therapeutic practices.

BliNK Biomedical SAS is a biotechnology company based in Lyon, France, founded in 2014. The company specializes in the discovery and development of monoclonal antibodies aimed at treating life-threatening diseases, particularly in the field of immuno-oncology. Its lead program focuses on a monoclonal antibody that targets an immune checkpoint, enhancing the body's immune response against tumors. BliNK Biomedical employs a unique B cell technology platform that facilitates the selection and isolation of specific antibody-producing cells from various species, including humans and animals. This innovative approach allows researchers to efficiently identify and develop next-generation anti-tumor therapeutics targeting novel immuno-oncology and immune-checkpoint pathways.

Eden Games SAS operates as an independent game studio. The company offers Gear.Club, a range of options for the cars that collect, upgrade, and customize exotic vehicles. It provides game franchises on PlayStation systems. Eden Games SAS was formerly known as Eden Studios and changed its name to Eden Games SAS in September 2003. The company was founded in 1998 and is based in Lyon, France. Eden Games SAS operates as a subsidiary of Torque Esports Corp.

Sensee is a French company based in Paris, specializing in the design and manufacturing of eyeglasses, sunglasses, and contact lenses for men, women, and children. Founded in October 2011, Sensee offers a diverse range of eyewear, including various frame styles such as square, classic, driver, rectangle, and round, as well as screen glasses. The company markets its products through both physical retail locations in cities like Paris, Marseille, Lyon, Toulouse, and Bordeaux, and its online platform. With a customer base exceeding 200,000 users, Sensee operates as a subsidiary of Acuitis Optical & Hearing Limited, reflecting its commitment to providing accessible and stylish eyewear options.

SantéVet is a leader in the animal health insurance sector, established in 2003. The company specializes in providing a range of insurance policies for pets, including dogs, cats, and smaller animals like hamsters and parrots. Its offerings allow pet owners to receive total or partial reimbursement for veterinary expenses, covering incidents such as accidents, illnesses, vaccinations, and therapeutic food. With a turnover of €20 million and a workforce of over 80 employees, SantéVet is recognized for the quality of its products and services by both clients and veterinary professionals. The company holds ISO 9001 certification, reflecting its commitment to high standards in customer service and operational excellence.

Adocia SA is a clinical-stage biotechnology company based in Lyon, France, that focuses on developing formulations of pre-approved therapeutic proteins and peptides for diabetes and other metabolic diseases. The company utilizes its proprietary BioChaperone technology platform to enhance the effectiveness and safety of these therapeutic proteins. Adocia's clinical product pipeline features formulations such as BioChaperone Lispro, which includes ultra-rapid insulin analogs, and BioChaperone Combo, a combination of basal and rapid-acting insulin. Additionally, it is developing BioChaperone Glucagon, an aqueous formulation aimed at treating hypoglycemia. The preclinical pipeline includes innovative combinations, such as BioChaperone LisPram and BioChaperone Glargine GLP-1, targeting diabetes and obesity. Adocia also has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to further develop and commercialize its products in China and other regions. Founded in 2005, Adocia strives to improve treatment options for individuals with metabolic disorders.

Adocia SA is a clinical-stage biotechnology company based in Lyon, France, that focuses on developing formulations of pre-approved therapeutic proteins and peptides for diabetes and other metabolic diseases. The company utilizes its proprietary BioChaperone technology platform to enhance the effectiveness and safety of these therapeutic proteins. Adocia's clinical product pipeline features formulations such as BioChaperone Lispro, which includes ultra-rapid insulin analogs, and BioChaperone Combo, a combination of basal and rapid-acting insulin. Additionally, it is developing BioChaperone Glucagon, an aqueous formulation aimed at treating hypoglycemia. The preclinical pipeline includes innovative combinations, such as BioChaperone LisPram and BioChaperone Glargine GLP-1, targeting diabetes and obesity. Adocia also has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to further develop and commercialize its products in China and other regions. Founded in 2005, Adocia strives to improve treatment options for individuals with metabolic disorders.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.